Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

Weiwei Mao, Mengmeng Ning, Zhiqing Liu, Qingzhang Zhu, Ying Leng, Ao Zhang

Research output: Contribution to journal › Article

26 Citations (Scopus)

Abstract

A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC 50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.

Original languageEnglish (US)
Pages (from-to)2982-2991
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number9
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Glucokinase
Pharmacokinetics
Chemical activation
Pharmacology
Derivatives
Glucose
Merging
Plasmas
benzamide

Keywords

  • Aminothiazole
  • Benzamide derivatives
  • Glucokinase activator
  • Privileged-fragment-merging
  • Type 2 diabetes (T2D)

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. / Mao, Weiwei; Ning, Mengmeng; Liu, Zhiqing; Zhu, Qingzhang; Leng, Ying; Zhang, Ao.

In: Bioorganic and Medicinal Chemistry, Vol. 20, No. 9, 01.05.2012, p. 2982-2991.

Research output: Contribution to journal › Article

Mao, W, Ning, M, Liu, Z, Zhu, Q, Leng, Y & Zhang, A 2012, 'Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators', Bioorganic and Medicinal Chemistry, vol. 20, no. 9, pp. 2982-2991. https://doi.org/10.1016/j.bmc.2012.03.008
Mao W, Ning M, Liu Z, Zhu Q, Leng Y, Zhang A. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. Bioorganic and Medicinal Chemistry. 2012 May 1;20(9):2982-2991. https://doi.org/10.1016/j.bmc.2012.03.008
Mao, Weiwei ; Ning, Mengmeng ; Liu, Zhiqing ; Zhu, Qingzhang ; Leng, Ying ; Zhang, Ao. / Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. In: Bioorganic and Medicinal Chemistry. 2012 ; Vol. 20, No. 9. pp. 2982-2991.
@article{35c3b835e3f6415d80d0cf91231978fb,
title = "Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators",
abstract = "A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC 50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.",
keywords = "Aminothiazole, Benzamide derivatives, Glucokinase activator, Privileged-fragment-merging, Type 2 diabetes (T2D)",
author = "Weiwei Mao and Mengmeng Ning and Zhiqing Liu and Qingzhang Zhu and Ying Leng and Ao Zhang",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.bmc.2012.03.008",
language = "English (US)",
volume = "20",
pages = "2982--2991",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

AU - Mao, Weiwei

AU - Ning, Mengmeng

AU - Liu, Zhiqing

AU - Zhu, Qingzhang

AU - Leng, Ying

AU - Zhang, Ao

PY - 2012/5/1

Y1 - 2012/5/1

N2 - A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC 50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.

AB - A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC 50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.

KW - Aminothiazole

KW - Benzamide derivatives

KW - Glucokinase activator

KW - Privileged-fragment-merging

KW - Type 2 diabetes (T2D)

UR - http://www.scopus.com/inward/record.url?scp=84862819984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862819984&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2012.03.008

DO - 10.1016/j.bmc.2012.03.008

M3 - Article

VL - 20

SP - 2982

EP - 2991

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 9

ER -

Access to Document